Rice Hall James & Associates LLC Has $10.47 Million Stake in Evolus, Inc. (NASDAQ:EOLS)

Rice Hall James & Associates LLC boosted its stake in Evolus, Inc. (NASDAQ:EOLS) by 4.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 948,281 shares of the company’s stock after buying an additional 43,381 shares during the quarter. Rice Hall James & Associates LLC owned approximately 1.50% of Evolus worth $10,469,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. KBC Group NV acquired a new stake in Evolus in the 4th quarter valued at $49,000. Point72 Asset Management L.P. acquired a new position in Evolus in the third quarter worth $132,000. Dynamic Technology Lab Private Ltd acquired a new position in Evolus in the third quarter worth $191,000. China Universal Asset Management Co. Ltd. boosted its stake in Evolus by 65.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company’s stock worth $197,000 after purchasing an additional 4,780 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new position in Evolus in the third quarter worth $212,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Friday. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Evolus in a research note on Tuesday, January 21st. Finally, Barclays boosted their target price on Evolus from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, January 27th.

Evolus Trading Down 2.0 %

EOLS stock opened at $14.74 on Tuesday. The company has a market cap of $933.34 million, a P/E ratio of -16.20 and a beta of 1.33. Evolus, Inc. has a twelve month low of $9.25 and a twelve month high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The business has a fifty day moving average of $12.13 and a 200-day moving average of $14.00.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.